Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Estimation of SARS-CoV-2 infection fatality rate by real-time antibody screening of blood donors

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. All-cause mortality due to bacteraemia during a 60-day non-physician healthcare worker strike

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Dabigatran and The Risk of Staphylococcus Aureus Bacteremia- A Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Antibody-dependent neutralizing capacity of the SARS-CoV-2 vaccine BNT162b2 with and without previous COVID-19 priming

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Investigating the inflammation marker neutrophil-to-lymphocyte ratio in Danish blood donors with restless legs syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Risk Factors for Being Seronegative following SARS-CoV-2 Infection in a Large Cohort of Health Care Workers in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: The pandemic due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has tremendous consequences for our societies. Knowledge of the seroprevalence of SARS-CoV-2 is needed to accurately monitor the spread of the epidemic and to calculate the infection fatality rate (IFR). These measures may help the authorities make informed decisions and adjust the current societal interventions. The objective was to perform nationwide real-time seroprevalence surveying among blood donors as a tool to estimate previous SARS-CoV-2 infections and the population-based IFR.

METHODS: Danish blood donors aged 17-69 years giving blood 6 April to 3 May were tested for SARS-CoV-2 immunoglobulin M and G antibodies using a commercial lateral flow test. Antibody status was compared between geographical areas, and an estimate of the IFR was calculated. Seroprevalence was adjusted for assay sensitivity and specificity taking the uncertainties of the test validation into account when reporting the 95% confidence intervals (CIs).

RESULTS: The first 20 640 blood donors were tested, and a combined adjusted seroprevalence of 1.9% (95% CI, .8-2.3) was calculated. The seroprevalence differed across areas. Using available data on fatalities and population numbers, a combined IFR in patients <70 years is estimated at 89 per 100 000 (95% CI, 72-211) infections.

CONCLUSIONS: The IFR was estimated to be slightly lower than previously reported from other countries not using seroprevalence data. The IFR is likely severalfold lower than the current estimate. We have initiated real-time nationwide anti-SARS-CoV-2 seroprevalence surveying of blood donations as a tool in monitoring the epidemic.

Original languageEnglish
JournalClinical infectious diseases : an official publication of the Infectious Diseases Society of America
Volume72
Issue number2
Pages (from-to)249-253
Number of pages5
ISSN1058-4838
DOIs
Publication statusPublished - 27 Jan 2021

    Research areas

  • COVID-19, emerging infectious disease, epidemic monitoring, SARS-CoV-2, seroprevalence, Humans, Middle Aged, Seroepidemiologic Studies, Antibodies, Viral, Young Adult, Blood Donors, Adolescent, Adult, Aged

ID: 61694921